PRINCETON, NJ (October 4, 2004) – Bristol-Myers Squibb Co. announced this week the submission of a New Drug Application to the U.S. Food & Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.
In the European Union, the company also submitted a marketing authorizationapplication for entecavir to the European Medicines Evaluation Agency.
Entecavir is an investigational oral antiviral that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.
Bristol-Myers Squibb is a global pharmaceutical and related health careproducts company.
